DiaCarta Receives CE/IVD for its New COVID 19 test that Identifies Delta Plus and New Variants
UF Innovate | Sid Martin Biotech alum DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel oncology tests using liquid biopsy, announced that its new QuantiVirus™ SARS-CoV-2 Variant Detection Test received the CE/IVD marking and therefore, can now be commercialized within the EU and rest of the world.
COVID-19 Testing Method Gives Results Within 1 Second
Researchers from the University of Florida and Taiwan’s National Chiao Tung University have developed a rapid and sensitive testing method for COVID-19 biomarkers. Their findings were recently published in the Journal of Vacuum Science & Technology B.
